Literature DB >> 33564391

Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study.

Jozsef Attila Szasz1, Dragos Catalin Jianu2, Mihaela Adriana Simu2, Viorelia Adelina Constantin1, Adriana Octaviana Dulamea3, Koray Onuk4, Diana Popescu5, Mihai-Titus Vasile6, Bogdan Ovidiu Popescu7, Alfonso Fasano8,9, Ovidiu Alexandru Bajenaru6.   

Abstract

OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) in 18 countries. Overall, the study enrolled 2615 patients. The aim was to determine the proportion of patients with advanced Parkinson's disease (APD) versus non-APD from MDCs and to uncover the clinical burden of APD, as well as a correlation between overall assessment of APD and several indicators of APD. The advanced stage of the disease and severity were assessed by investigators using their clinical judgement. Data were collected during a single visit between February 2015 and January 2016. Agreement on physician judgement of APD diagnosis and fulfillment of at least one previously established APD indicator was calculated. Motor and nonmotor symptoms (NMSs), activities of daily living, treatment complications, quality of life (QoL), conventional treatments, and device-aided therapy (DAT) eligibility were assessed. Here, country-specific results of 161 Romanian patients with PD are presented. In total, 59.0% of patients were diagnosed with APD and 78.8% met at least one APD indicator. There was only moderate agreement between clinical judgement of APD and overall fulfillment of APD indicators. All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment.
Copyright © 2021 Jozsef Attila Szasz et al.

Entities:  

Year:  2021        PMID: 33564391      PMCID: PMC7850828          DOI: 10.1155/2021/6635618

Source DB:  PubMed          Journal:  Parkinsons Dis        ISSN: 2042-0080


  4 in total

1.  Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience.

Authors:  József Attila Szász; Viorelia Adelina Constantin; Károly Orbán-Kis; Ligia Ariana Bancu; Simona Maria Bataga; Marius Ciorba; Előd Nagy; Mircea Radu Neagoe; István Mihály; Róbert Máté Szász; Krisztina Kelemen; Mihaela Simu; Szabolcs Szatmári
Journal:  Pharmaceutics       Date:  2022-05-24       Impact factor: 6.525

2.  Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.

Authors:  Alfonso Fasano; Victor S C Fung; Klaus Seppi; Zvezdan Pirtosek; Annamária Takáts; Ali Alobaidi; Koray Onuk; Lars Bergmann; Juan Carlos Parra; Bulent Elibol
Journal:  Acta Neurol Scand       Date:  2022-05-24       Impact factor: 3.915

3.  Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease.

Authors:  József Attila Szász; Viorelia Adelina Constantin; Károly Orbán-Kis; Ligia Ariana Bancu; Marius Ciorba; István Mihály; Előd Ernő Nagy; Róbert Máté Szász; Krisztina Kelemen; Mihaela Adriana Simu; Szabolcs Szatmári
Journal:  Brain Sci       Date:  2021-06-22

4.  Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis.

Authors:  Mihaela Adriana Simu; Dragoș Cătălin Jianu; Adriana Octaviana Dulamea; Viorelia Adelina Constantin; Diana Popescu; Juan Carlos Parra; József Attila Szász
Journal:  Brain Sci       Date:  2021-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.